Wendye Robbins net worth and biography

Wendye Robbins Biography and Net Worth

Director of RAPT Therapeutics
Wendye Robbins M.D. serves as Independent Director of the Company. She has served as President and CEO of Blade Therapeutics since August 2016 (and previously held the title of Interim CEO from May 2015 to July 2016). Dr. Robbins has also served as an independent consultant to venture investors in company formation and translational biology. Dr. Robbins has also served on the faculty at Stanford University School of Medicine in the Department of Anesthesia, Perioperative Care, and Pain Medicine since 2004. Dr. Robbins completed her residency in Anesthesiology at Johns Hopkins University School of Medicine, her internship in Internal Medicine at the University of Pennsylvania School of Medicine, and received her fellowship training in Pain Medicine from John Hopkins University School of Medicine. Dr. Robbins received an M.D. from The Medical College of Pennsylvania and a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley. Robbins’ extensive experience in the biopharmaceutical industry, her industry expertise and financial knowledge provide her with the qualifications and skills to serve as a director of our company.

What is Wendye Robbins' net worth?

The estimated net worth of Wendye Robbins is at least $312,006.00 as of March 14th, 2023. Dr. Robbins owns 14,900 shares of RAPT Therapeutics stock worth more than $312,006 as of June 7th. This net worth estimate does not reflect any other investments that Dr. Robbins may own. Learn More about Wendye Robbins' net worth.

How do I contact Wendye Robbins?

The corporate mailing address for Dr. Robbins and other RAPT Therapeutics executives is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. RAPT Therapeutics can also be reached via phone at (650) 489-9000 and via email at [email protected]. Learn More on Wendye Robbins' contact information.

Has Wendye Robbins been buying or selling shares of RAPT Therapeutics?

Wendye Robbins has not been actively trading shares of RAPT Therapeutics during the last quarter. Most recently, on Tuesday, March 14th, Wendye Robbins bought 2,500 shares of RAPT Therapeutics stock. The stock was acquired at an average cost of $18.99 per share, with a total value of $47,475.00. Following the completion of the transaction, the director now directly owns 14,900 shares of the company's stock, valued at $282,951. Learn More on Wendye Robbins' trading history.

Who are RAPT Therapeutics' active insiders?

RAPT Therapeutics' insider roster includes Dirk Brockstedt (Insider), William Ho (Insider), and Wendye Robbins (Director). Learn More on RAPT Therapeutics' active insiders.

Are insiders buying or selling shares of RAPT Therapeutics?

In the last twelve months, RAPT Therapeutics insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $47,475.00. In the last twelve months, insiders at the sold shares 11 times. They sold a total of 42,242 shares worth more than $980,966.74. The most recent insider tranaction occured on April, 19th when insider William Ho sold 5,000 shares worth more than $94,400.00. Insiders at RAPT Therapeutics own 5.5% of the company. Learn More about insider trades at RAPT Therapeutics.

Information on this page was last updated on 4/19/2023.

Wendye Robbins Insider Trading History at RAPT Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2023Buy2,500$18.99$47,475.0014,900View SEC Filing Icon  
5/10/2022Buy4,500$11.24$50,580.0013,800View SEC Filing Icon  
10/18/2021Buy500$30.70$15,350.00View SEC Filing Icon  
10/13/2021Buy400$29.69$11,876.00View SEC Filing Icon  
8/23/2021Buy1,475$31.39$46,300.25View SEC Filing Icon  
8/20/2021Buy600$29.53$17,718.00View SEC Filing Icon  
7/7/2021Buy1,000$30.18$30,180.007,400View SEC Filing Icon  
6/16/2021Buy700$31.54$22,078.006,600View SEC Filing Icon  
4/13/2021Buy700$19.46$13,622.005,800View SEC Filing Icon  
4/9/2021Buy600$21.12$12,672.004,826View SEC Filing Icon  
11/19/2020Buy500$16.08$8,040.005,100View SEC Filing Icon  
9/28/2020Buy500$28.70$14,350.006,350View SEC Filing Icon  
9/24/2020Buy200$28.00$5,600.005,750View SEC Filing Icon  
7/24/2020Buy900$22.47$20,223.005,050View SEC Filing Icon  
7/1/2020Buy2,600$26.01$67,626.003,550View SEC Filing Icon  
6/29/2020Buy1,600$25.77$41,232.003,550View SEC Filing Icon  
See Full Table

Wendye Robbins Buying and Selling Activity at RAPT Therapeutics

This chart shows Wendye Robbins's buying and selling at RAPT Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

RAPT Therapeutics Company Overview

RAPT Therapeutics logo
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $21.05
Low: $20.62
High: $21.50

50 Day Range

MA: $18.96
Low: $16.06
High: $21.34

2 Week Range

Now: $21.05
Low: $13.31
High: $32.45


221,120 shs

Average Volume

427,025 shs

Market Capitalization

$723.07 million

P/E Ratio


Dividend Yield



Yours Free! Top FIVE Dividend Stocks Right Now
This Ultimate Dividend Package contains an "A"-rated, ultra-safe dividend stock with a huge 8% yield, and one income expert's No. 1 dividend stock for a LIFETIME of income. 

Click here to get your FREE Ultimate Dividend Package.